| Abstrakt: |
Sema4, a patient-centered health intelligence company, today announced the launch of Sema4 Signal™, a new family of products and services providing data-driven precision oncology solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests. With its comprehensive suite of offerings, Sema4 Signal enables a holistic approach to support oncologists delivering precision medicine throughout a patient’s journey, from assessing the risk of cancer to analyzing cancer for treatment options and monitoring in remission. [ABSTRACT FROM PUBLISHER] |
